In a groundbreaking advancement in the treatment of opioid use disorder (OUD), researchers have demonstrated that integrating ketamine-assisted psychotherapy with mindfulness-based interventions significantly improves patient outcomes. This novel approach combines the pharmacological and psychotherapeutic benefits of ketamine—a dissociative anesthetic with emerging psychiatric applications—with the cognitive and emotional training of Mindfulness-Oriented Recovery Enhancement (MORE). The findings, derived from a rigorous randomized controlled trial, offer promising evidence for a more effective, multidimensional treatment paradigm that could reshape OUD therapy.
The opioid epidemic remains a critical public health crisis, with millions affected worldwide and a staggering toll in lives lost to overdose and addiction-related complications. Buprenorphine maintenance therapy has been a mainstay in managing OUD, providing partial agonism at opioid receptors to reduce cravings and withdrawal symptoms. However, relapse rates remain high, and additional therapeutic strategies are urgently needed to enhance recovery outcomes. The novel intervention studied here seeks to fill this therapeutic gap by combining buprenorphine with a synergistic psychopharmacological and behavioral approach.
This clinical trial enrolled 68 individuals diagnosed with OUD who were already receiving buprenorphine maintenance therapy. Participants were randomized to two arms: one group received the MORE intervention alone via telehealth, while the other group received MORE combined with ketamine-assisted psychotherapy (KAP). The MORE intervention is an 8-week program focusing on mindfulness training, reappraisal techniques, and savoring practices to help patients reconceptualize craving and negative affective states, bolster self-regulation, and foster positive emotional experiences. Participants in the KAP arm received two intramuscular ketamine doses—first a standard 0.5 mg/kg dose after week 5, followed by an optional increased dose up to 1.0 mg/kg one week later.
The administration of ketamine was carefully controlled and supervised, minimizing the risk of adverse events while maximizing the therapeutic potential of the drug’s rapid-acting psychotropic effects. Ketamine’s unique mechanism of action involves antagonism of NMDA receptors and modulation of glutamatergic transmission, which is believed to facilitate neuroplastic changes conducive to therapeutic breakthroughs. When paired with psychotherapeutic guidance, ketamine’s effects may catalyze lasting shifts in cognition and emotion, particularly relevant for disorders rooted in maladaptive reward and stress processing such as OUD.
The primary outcome evaluated was the frequency of drug use post-treatment. Remarkably, the group receiving the combined treatment of MORE plus ketamine-assisted psychotherapy demonstrated a significantly lower incidence of drug use compared to the group that participated in MORE alone. These findings indicate that ketamine, when integrated into a structured, mindfulness-based psychotherapeutic framework, may augment patients’ ability to resist opioid use beyond what behavioral interventions achieve independently.
Secondary outcomes shed further light on the intervention’s impact. Participants in the combined treatment arm reported substantially reduced cravings for opioids at follow-up assessments. Craving is a central driver of relapse in OUD, and attenuation of craving intensity represents a critical therapeutic target. While both groups experienced benefits, the additional ketamine exposure was associated with enhanced reductions in opioid desire, underscoring a potential neurobiological substrate for these clinical improvements.
Interestingly, the trial did not find meaningful differences between the two groups with respect to psychological distress or the extent of buprenorphine utilization. This suggests that although ketamine-assisted psychotherapy enhances cravings and drug use-related outcomes, it does not necessarily alter distress levels or medication adherence during the short term. This finding emphasizes that the intervention’s main advantage may reside in direct modulation of addictive behaviors and related cognitive processes rather than broader affective symptoms or medication compliance.
One of the most compelling aspects of the trial was the measurement of mindfulness-related processes. The researchers observed that individuals in the MORE plus KAP arm reported greater increases in mindfulness skills relative to those undergoing MORE only. These processes likely mediate the capacity to observe and tolerate craving and discomfort without succumbing to compulsive drug use, highlighting the synergistic effects of ketamine’s neuroplastic facilitation with mindfulness-based cognitive restructuring.
Furthermore, during ketamine administration sessions, a striking 85% of participants reported experiencing what investigators termed a “full mystical experience.” Such profound, often ineffable experiences have been previously linked to therapeutic benefits in psychedelic-assisted psychotherapy. In this study, the extent of mystical experience was predictive of subsequent reductions in opioid craving, pointing towards altered states of consciousness as an integral mediator of ketamine’s therapeutic efficacy.
Safety data from the trial were encouraging, with no serious ketamine-related adverse events reported. This is particularly significant given concerns about ketamine’s potential for abuse, psychotomimetic effects, and cardiovascular risks. The controlled clinical environment and judicious dosing appeared to mitigate these risks while delivering the desired psychotropic outcomes.
The trial’s single-blinded design—where assessors but not participants were blinded—allowed for rigorous data collection while maintaining participant engagement and safety during ketamine administration. This methodological choice strikes a balance between experimental control and ethical considerations inherent in psychopharmacological research involving psychoactive compounds.
Overall, this pioneering study affirms that intramuscular ketamine, when combined with the skillful delivery of mindfulness-oriented psychotherapy, represents a feasible, safe, and potentially potent treatment augmentation for opioid use disorder. The integration of biological and psychological modalities promises to enhance both craving reduction and relapse prevention, addressing critical challenges that have limited the effectiveness of existing treatments.
These findings open new avenues for research into how ketamine’s acute neurobiological effects can be harnessed within behavioral frameworks to promote sustained recovery. Future studies with larger cohorts, longer follow-ups, and mechanistic biomarker assessments will be crucial to validate and extend these promising results, as well as to explore personalization of combined treatments for diverse patient subgroups.
The confluence of ketamine’s neuroplastic properties with mindfulness training capitalizes on emerging neuroscience paradigms that highlight the brain’s capacity for adaptive rewiring in response to pharmacological and experiential inputs. The results suggest not only symptom relief but also transformative cognitive and affective change, potentially resetting pathological reward circuits that drive addiction.
Clinicians and policymakers should take note of these advancements, as incorporating ketamine-assisted psychotherapy into standard care models could substantially improve long-term recovery rates and reduce the burden of opioid addiction. Additional training for therapists in delivering KAP protocols alongside mindfulness interventions will be needed to translate these findings into widespread clinical practice.
The study’s promising outcomes also contribute to a broader conversation about integrating psychedelic-assisted therapies into mental health care. By demonstrating safety and efficacy in a severely impaired population, the research challenges stigma and regulatory hurdles surrounding ketamine use, reinforcing its position as a therapeutic agent with distinct advantages.
In conclusion, this innovative randomized controlled trial provides compelling evidence that ketamine-assisted mindfulness-oriented recovery enhancement can revolutionize treatment approaches for opioid use disorder. By addressing core mechanisms of craving and relapse within a comprehensive biopsychosocial framework, this approach offers hope for improved sobriety, quality of life, and reduced societal impact of the opioid epidemic. The results lay a strong foundation for expanded research and development of combined pharmacological-behavioral therapies targeting substance use disorders.
Subject of Research: The efficacy and safety of ketamine-assisted psychotherapy combined with Mindfulness-Oriented Recovery Enhancement (MORE) in treating opioid use disorder (OUD).
Article Title: Ketamine-assisted Mindfulness-Oriented Recovery Enhancement for opioid use disorder: a randomized controlled trial.
Article References:
Garland, E.L., Lewis, B.R., Thielking, P. et al. Ketamine-assisted Mindfulness-Oriented Recovery Enhancement for opioid use disorder: a randomized controlled trial. Nat. Mental Health (2026). https://doi.org/10.1038/s44220-026-00625-5
Image Credits: AI Generated
